Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Nasus Pharma Ltd. (NSRX) had Tangible Shareholders Equity of $2.77M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$4.86M |
|
-- |
|
-- |
|
$5.00M |
|
$2.16M |
|
-- |
|
-- |
|
$2.24M |
|
$2.77M |
|
|
Tangible Shareholders Equity |
$2.77M |
$2.77M |
|
-- |
|
| Cash Flow Statement Financials | |
$-4.92M |
|
$-3.01M |
|
$8.92M |
|
$0.31M |
|
$1.29M |
|
$0.98M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|